Development of a mel cell-derived allograft mouse model for cancer research
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Min Young | - |
dc.contributor.author | Choi, Sungwoo | - |
dc.contributor.author | Lee, Seol Eui | - |
dc.contributor.author | Kim, Ji Sook | - |
dc.contributor.author | Son, Seung Han | - |
dc.contributor.author | Lim, Young Soo | - |
dc.contributor.author | Kim, Bang-Jin | - |
dc.contributor.author | Ryu, Buom-Yong | - |
dc.contributor.author | Uversky, Vladimir N. | - |
dc.contributor.author | Lee, Young Jin | - |
dc.contributor.author | Kim, Chul Geun | - |
dc.date.available | 2020-04-24T02:21:12Z | - |
dc.date.issued | 2019-11 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/39067 | - |
dc.description.abstract | Murine erythroleukemia (MEL) cells are often employed as a model to dissect mechanisms of erythropoiesis and erythroleukemia in vitro. Here, an allograft model using MEL cells resulting in splenomegaly was established to develop a diagnostic model for isolation/quantification of metastatic cells, anti-cancer drug screening, and evaluation of the tumorigenic or metastatic potentials of molecules in vivo. In this animal model, circulating MEL cells from the blood stream were successfully isolated and quantified with an additional in vitro cultivation step. In terms of the molecular-pathological analysis, we were able to successfully evaluate the functional discrimination between methyl-CpG-binding domain 2 (Mbd2) and p66α in erythroid differentiation, and tumorigenic potential in spleen and blood stream of allograft model mice. In addition, we found that the number of circulating MEL cells in anti-cancer drug-treated mice was dose-dependently decreased. Our data demonstrate that the newly established allograft model is useful to dissect erythroleukemia pathologies and non-invasively provides valuable means for isolation of metastatic cells, screening of anti-cancer drugs, and evaluation of the tumorigenic potentials. © 2019 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI AG | - |
dc.title | Development of a mel cell-derived allograft mouse model for cancer research | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/cancers11111707 | - |
dc.identifier.bibliographicCitation | Cancers, v.11, no.11 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000502290100089 | - |
dc.identifier.scopusid | 2-s2.0-85074614404 | - |
dc.citation.number | 11 | - |
dc.citation.title | Cancers | - |
dc.citation.volume | 11 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | Allograft | - |
dc.subject.keywordAuthor | Cancer treatment | - |
dc.subject.keywordAuthor | Circulating tumor cells | - |
dc.subject.keywordAuthor | Erythroleukemia | - |
dc.subject.keywordAuthor | Liquid biopsy | - |
dc.subject.keywordPlus | fluorouracil | - |
dc.subject.keywordPlus | hexamethylenebisacetamide | - |
dc.subject.keywordPlus | methyl CpG binding protein 2 | - |
dc.subject.keywordPlus | protein p66 | - |
dc.subject.keywordPlus | allograft | - |
dc.subject.keywordPlus | animal cell | - |
dc.subject.keywordPlus | animal experiment | - |
dc.subject.keywordPlus | animal model | - |
dc.subject.keywordPlus | animal tissue | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | cancer research | - |
dc.subject.keywordPlus | carcinogenicity | - |
dc.subject.keywordPlus | cell differentiation | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | drug screening | - |
dc.subject.keywordPlus | erythroid cell | - |
dc.subject.keywordPlus | erythroleukemia | - |
dc.subject.keywordPlus | erythroleukemia cell | - |
dc.subject.keywordPlus | metastasis potential | - |
dc.subject.keywordPlus | mouse | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | protein analysis | - |
dc.subject.keywordPlus | randomized controlled trial | - |
dc.subject.keywordPlus | RNA interference | - |
dc.subject.keywordPlus | splenomegaly | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.